Meta-analysis challenges statin use in cardio treatment

Meta-analysis of data from 20 cardiovascular-therapy trials, including 4S and Jupiter, reveals that low levels of HDL-cholesterol remain a significant risk even while statin therapies are being used to treat elevated LDL-cholesterol levels. The findings disprove the popular notion among doctors that by lowering LDL cholesterol with a statin, such other factors as HDL cholesterol don't matter.

"That's not true," says senior investigator Richard Karas of the Tufts Medical Center. He and colleagues established median baseline and on-treatment HDL-cholesterol levels (45 and 48 mg/dL, respectively) from the 20 trials. The levels were similar among statin-treated patients and controls, according to Heartwire.

The researchers adjusted for LDL-cholesterol levels and age. They found that a 10-mg/dL decrease in HDL-cholesterol levels was associated with 7.1 more myocardial infarctions per 1000 patient-years in statin-treated patients versus 8.3 among healthy controls. The inverse association between HDL-cholesterol levels and MI did not differ statistically between the statin-treated and control patients, and similar results were observed with other cardiovascular disease outcomes.

- here's the article (registration required)

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.